HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ishizaka, K. Articles by Okudaira, H. Search for Related Content PubMed Articles by Ishizaka, K. Articles by Okudaira, H.

Reaginic Antibody Formation in the Mouse

I. Antibody-Mediated Suppression of Reaginic Antibody Formation¹

From the Department of Medicine and Microbiology, Johns Hopkins University, School of Medicine at the Good Samaritan Hospital, Baltimore, Maryland 21239

Abstract

DBA/1 mice were immunized by an intraperitoneal injection of 0.2 to 1.0 µg of ovalbumin precipitated with aluminum hydroxide gel and the antibody response was observed. Both reaginic and ₁ antibodies were detected in the serum 10 days after the immunization and the antibody formation persisted for more than 1 month. The animals showed a secondary reaginic antibody response upon booster injection. An intravenous injection of 80 µg N of mouse anti-ovalbumin IgG antibody into the immunized mice within 24 hr after primary immunization prevented both reaginic and ₁ antibody responses for a period of over 3 weeks, during which time passive antibody was detectable in the serum. Evidence was obtained that an essentially normal immune response followed after the passive antibody was catabolized. Both reaginic and ₁ antibodies were detected in the serum 40 days after immunization. An increased interval between immunization and passive antibody resulted in progressively decreasing efficiency of inhibition of the antibody response. Passive administration of IgG antibody did not terminate pre-existing reaginic antibody formation nor suppress secondary antibody response.

Footnotes

¹ This work was supported by Research Grant GB-27682 from the National Science Foundation and from the John A. Hartford Foundation. This is Publication 33 from the O'Neill Laboratories, the Good Samaritan Hospital.